Advertisement
UK markets close in 8 hours 26 minutes
  • FTSE 100

    8,247.79
    -33.76 (-0.41%)
     
  • FTSE 250

    20,363.43
    0.00 (0.00%)
     
  • AIM

    768.03
    0.00 (0.00%)
     
  • GBP/EUR

    1.1850
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.2675
    -0.0011 (-0.09%)
     
  • Bitcoin GBP

    48,570.78
    +357.86 (+0.74%)
     
  • CMC Crypto 200

    1,277.54
    -6.25 (-0.49%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CRUDE OIL

    81.38
    +0.55 (+0.68%)
     
  • GOLD FUTURES

    2,327.90
    -2.90 (-0.12%)
     
  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     
  • HANG SENG

    18,105.44
    +32.54 (+0.18%)
     
  • DAX

    18,177.62
    -147.96 (-0.81%)
     
  • CAC 40

    7,662.30
    0.00 (0.00%)
     

Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

Ardelyx, Inc.
Ardelyx, Inc.

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com